Auris Medical Holding AG (NASDAQ:EARS) was the target of a significant decrease in short interest in the month of September. As of September 28th, there was short interest totalling 1,066,831 shares, a decrease of 39.5% from the September 14th total of 1,762,462 shares. Based on an average daily volume of 2,051,643 shares, the short-interest ratio is currently 0.5 days. Currently, 6.0% of the shares of the company are sold short.
Separately, Eurobank EFG began coverage on Auris Medical in a report on Monday, October 8th. They issued a “buy” rating and a $2.50 price objective on the stock.
Shares of EARS stock opened at $0.98 on Friday. Auris Medical has a fifty-two week low of $0.23 and a fifty-two week high of $9.50.
An institutional investor recently bought a new position in Auris Medical stock. Bellevue Group AG bought a new position in Auris Medical Holding AG (NASDAQ:EARS) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 193,125 shares of the biotechnology company’s stock, valued at approximately $151,000. Bellevue Group AG owned about 3.16% of Auris Medical as of its most recent SEC filing. Institutional investors own 17.96% of the company’s stock.
Auris Medical Company Profile
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
Featured Article: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.